CVS: GLP-1 drugs pay off for employers only below $350 a month

what happened

CVS Health said employers and other health plan sponsors would break even on GLP-1 drugs if monthly prices dropped below $350. The company argues that fewer hospital stays and emergency room visits could offset drug spending only at that level. Its analysis of Aetna claims data, reported by Reuters, found that at current prices the drugs add to total costs for patients with obesity, diabetes or other conditions.

The study compared newly treated patients taking Mounjaro, Ozempic, Zepbound or Wegovy from Eli Lilly and Novo Nordisk with similar patients who did not take them, over periods of up to three years. Emergency room visits fell 10-12% in the first and second years, and hospitalizations dropped 34-42% among those still on the drugs after three years. Over that span, plan sponsors saved $9,400 per person on medical bills but paid $13,300 more for prescriptions, a net added cost of $3,900 per patient.

Coverage is already shrinking: about 14% of companies have dropped or plan to drop obesity drugs in 2027 as premiums are expected to rise more than 9%.

why it matters

The findings come from CVS's own claims analysis rather than an independent trial. For the market, the key signal is that employers are narrowing coverage, which could limit demand for Lilly and Novo's drugs unless prices come down.

market impact

Eli Lilly and Novo Nordisk: employers cutting GLP-1 coverage could weigh on demand for their obesity drugs.

• ▼Eli Lilly shares pressure down — employers narrowing GLP-1 coverage could reduce prescriptions for its obesity drugs
• ▼Novo Nordisk shares pressure down — employers dropping coverage could cut demand for its GLP-1 drugs

tags

instruments